Russell Investments Group
IKT icon

Russell Investments Group’s Inhibikase Therapeutics IKT Stock Holding History

Russell Investments Group’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.9K Sell
6,517
-4,297
-40% -$7.63K ﹤0.01% 3776
2025
Q4 		$22.2K Buy
10,814
+3,112
+40% +$4.95K ﹤0.01% 3598
2025
Q3 		$12.5K Buy
+7,702
New +$13.3K ﹤0.01% 3732

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Russell Investments Group's IKT Position: Q1 2026 in Review

Russell Investments Group reduced its Inhibikase Therapeutics (IKT) stake by 40% in Q1 2026, selling an estimated $7.63K and leaving 6,517 shares worth $10.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3776.

Russell Investments Group first reported a position in IKT in Q3 2025 and has held it in 3 quarters since. The position peaked at $22.2K in Q4 2025. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Russell Investments Group held 6,517 shares of Inhibikase Therapeutics worth $10.9K as of Q1 2026.
  • Russell Investments Group sold 4,297 Inhibikase Therapeutics shares in Q1 2026, an estimated $7.63K.
  • Inhibikase Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #3776 holding.
  • Russell Investments Group first reported a position in Inhibikase Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Russell Investments Group's Inhibikase Therapeutics position peaked at $22.2K in Q4 2025.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.